ders "can vote with their feet", on February 22, 2013 Elan announced a US$1 billion share repurchase programme and noted that "We greatly value our shareholder relationships and the access to equity capital these relationships give us and we appreciate the time horizon of many of our long term holders. We will continue to work on ways to unlock incremental value to their direct benefit". Notably, Elan failed to disclose that it had received Royalty Pharma's Proposal.
On February 25, 2013, after Royalty Pharma released the Proposal Announcement, Elan stated publicly that it would consider any credible proposal, implying that Royalty Pharma's Proposal was not credible.
On March 4, 2013, Elan announced a plan to distribute 20 percent of the Tysabri Royalty to shareholders through dividends. Deutsche Bank and RBC Capital Markets have calculated that this would imply a dividend yield of only 1-2 percent in the short term, and this announcement provides no further clarity about Elan's plans for the remaining 80 percent of the Tysabri Royalty. The Elan CEO made a number of remarks in an interview on that day that rejected entertaining any discussions with Royalty Pharma, stating that:
"We're not in any discussions with [Royalty Pharma] at all on any topic and we don't see any need to have those discussions."
"We don't see Royalty Pharma as a credible counterparty to have any strategic discussions with. We're not looking for any price."
Accordingly, Royalty Pharma believes that Elan is still not focused on maximising shareholder value, and that Elan Shareholders should treat Elan's recent change of heart regarding returning cash to Elan Shareholders with scepticism.
The reaction of analysts to the Tysabri Transaction
Following the announcement of the Tysabri Transaction, four analysts (AlphaValue, Deutsche Bank, RBC Capital Markets, and UBS) cut their ratings on the Elan Stock and nine analysts (AlPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Related biology technology :1
. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million2
. Cowen Healthcare Royalty Partners Raises $1 Billion3
. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology4
. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz5
. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California6
. AVANIR Pharmaceuticals To participate in two conferences in March7
. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says8
. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections9
. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies10
. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 201311
. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks